The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Second interim analysis of Global Investigation of Therapeutic Decisions in Unresectable HCC and of its Treatment with Sorafenib (GIDEON): U.S. versus global perspective on patient and disease characteristics, treatment history, and sorafenib use.
Alec Goldenberg
No relevant relationships to disclose
Anthony B. El-Khoueiry
Consultant or Advisory Role - Bayer; Onyx
Honoraria - Bayer; Onyx
Research Funding - Bayer; Onyx
Robert C. G. Martin
Honoraria - Bayer; Onyx
Alan Paul Venook
Research Funding - Bayer; Bayer; Onyx; Onyx
Parvez Mantry
Consultant or Advisory Role - Bayer; Onyx
Honoraria - Bayer; Onyx
Research Funding - Bayer; Onyx
Pierre Michel Gholam
Consultant or Advisory Role - Onyx
Honoraria - Onyx
Research Funding - Onyx
Brendan McGuire
Consultant or Advisory Role - Onyx
Honoraria - Onyx
Research Funding - Onyx
Arun Sanyal
Consultant or Advisory Role - Onyx (U)
Research Funding - Bayer; Onyx
Jean-Francois Geschwind
Consultant or Advisory Role - Bayer; Biocompatibles; Guerbet; Nordion
Research Funding - Bayer; Biocompatibles; CeloNova; ContextVision; Genentech; Nordion; Phillips Medical; RSNA
Jorge A. Marrero
Consultant or Advisory Role - Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Onyx; Onyx
Research Funding - Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Onyx; Onyx